151 related articles for article (PubMed ID: 3031174)
1. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
[TBL] [Abstract][Full Text] [Related]
2. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
[TBL] [Abstract][Full Text] [Related]
3. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
Roberts PL; Duncan BE; Raybould TJ; Watson DH
J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
5. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
Chan WL; Lukig ML; Liew FY
J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
Zaia JA; Palmer EL; Feorino PM
J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
[TBL] [Abstract][Full Text] [Related]
7. Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.
Asher LV; Walz MA; Notkins AL
Am J Obstet Gynecol; 1978 Aug; 131(7):788-91. PubMed ID: 210669
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
9. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge.
Landolfi V; Zarley CD; Abramovitz AS; Figueroa N; Wu SL; Blasiak M; Ishizaka ST; Mishkin EM
Vaccine; 1993; 11(4):407-14. PubMed ID: 8385842
[TBL] [Abstract][Full Text] [Related]
10. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
11. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
Kino Y
Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
[No Abstract] [Full Text] [Related]
12. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
[TBL] [Abstract][Full Text] [Related]
13. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
[TBL] [Abstract][Full Text] [Related]
14. Immunological memory to herpes simplex virus type 1 glycoproteins B and D in mice.
Blacklaws BA; Nash AA
J Gen Virol; 1990 Apr; 71 ( Pt 4)():863-71. PubMed ID: 2157799
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast.
Kino Y; Nozaki C; Nakatake H; Mizuno K; Mori R
Vaccine; 1989 Apr; 7(2):155-60. PubMed ID: 2546329
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
Bernstein DI; Miller RL; Harrison CJ
J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
[TBL] [Abstract][Full Text] [Related]
18. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
Dix RD; Mills J
J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
20. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
Dix RD; Pereira L; Baringer JR
Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
